Results 21 to 30 of about 54,884 (249)
Adoptive T-Cell Therapy for Cancer [PDF]
, 2016 Recent developments have demonstrated that immunotherapies are capable of achieving durable antitumor responses in patients with metastatic cancer. One modality that has been able to induce durable complete regressions in patients with melanoma has been adoptive cell therapy (ACT).
James C, Yang, Steven A, Rosenberg
openaire +2 more sources
CAR-T Cell Performance: How to Improve Their Persistence?
Frontiers in Immunology, 2022 Adoptive cell therapy with T cells reprogrammed to express chimeric antigen receptors (CAR-T cells) has been highly successful in patients with hematological neoplasms. However, its therapeutic benefits have been limited in solid tumor cases.
Gina López-Cantillo +4 more
doaj +1 more source
Adoptive T cell therapy for ovarian cancer. [PDF]
Gynecol OncolAlthough ovarian cancer patients typically respond to standard of care therapies, including chemotherapy and DNA repair inhibitors, the majority of tumors recur highlighting the need for alternative therapies. Ovarian cancer is an immunogenic cancer in which the accumulation of tumor infiltrating lymphocytes (TILs), particularly T cells, is associated ...
Gitto SB, Ihewulezi CJN, Powell DJ.
europepmc +3 more sources
Adoptive T‐cell therapy for cancer: The era of engineered T cells [PDF]
European Journal of Immunology, 2015 Tumors originate from a number of genetic events that deregulate homeostatic mechanisms controlling normal cell behavior. The immune system, devoted to patrol the organism against pathogenic events, can identify transformed cells, and in several cases cause their elimination.
BONINI , MARIA CHIARA, Mondino A.
openaire +3 more sources
Adoptive T cell therapy: Addressing challenges in cancer immunotherapy
Journal of Translational Medicine, 2005 Adoptive T cell therapy involves the ex vivo selection and expansion of effector cells for the treatment of patients with cancer. In this review, the advantages and limitations of using antigen-specific T cells are discussed in counterpoint to vaccine ...
Yee Cassian
doaj +1 more source
Frontiers in Oncology, 2022 Peripheral T-cell lymphoma (PTCL) is a type of highly heterogeneous non-Hodgkin lymphoma with a poor prognosis and lack of effective targeted therapies. Adoptive T-cell therapy has been successfully used in the treatment of B-cell malignancies.
Yuan Chen +6 more
doaj +1 more source
Synthetic Antigen‐Presenting Cells for Adoptive T Cell Therapy [PDF]
Advanced Therapeutics, 2021 Abstract Adoptive T cell therapies are transforming the treatment of solid and liquid tumors, yet their widespread adoption is limited in part by the challenge of generating functional cells. T cell activation and expansion using conventional antigen‐presenting cells (APCs) is unreliable due to the variable quality of donor‐derived ...
Shreyas N. Dahotre +3 more
openaire +2 more sources
Frontiers in Immunology, 2019 The successful generation of T cell-mediated immunity for the treatment of cancer has been a major focal point of research. One of the critical strategies of cancer immunotherapy is to efficiently activate antigen-specific CD8 T cells in the ...
Jin-Zhi Lai +5 more
doaj +1 more source
Frontiers in Immunology, 2023 Recurrent neoepitopes are cancer-specific antigens common among groups of patients and therefore ideal targets for adoptive T cell therapy. The neoepitope FSGEYIPTV carries the Rac1P29S amino acid change caused by a c.85C>T missense mutation, which is
Lena Immisch +15 more
doaj +1 more source
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer
Journal of Translational Medicine, 2012 A summit on cellular therapy for cancer discussed and presented advances related to the use of adoptive cellular therapy for melanoma and other cancers. The summit revealed that this field is advancing rapidly.
Stroncek David F +17 more
doaj +1 more source